Announcements Trials

Browse Landscape

Phase

Status

Recruiting 23 Completed 17 Active not recruiting 9 Withdrawn 5 Unknown 5 Terminated 5 Suspended 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Castration Resistant Prostate Cancer (mCRPC) 1

Interventions

Specimen Handling 12 Magnetic Resonance Spectroscopy 10 Cyclophosphamide 10 Cisplatin 7 Bevacizumab 7 pembrolizumab 6 Radiosurgery 6 Oxaliplatin 5 Nivolumab 5 Irinotecan 5 Fluorouracil 5 Everolimus 5 Capecitabine 5 Biopsy 5 venetoclax 4 fludarabine 4 S 1 (combination) 4 Prednisone 4 Leucovorin 4 Gemcitabine 4 Etoposide 4 Drug Therapy 4 Doxorubicin 4 Azacitidine 4 fludarabine phosphate 3 Vincristine 3 Taxes 3 Tacrolimus 3 Surveys and Questionnaires 3 Surgical Procedures, Operative 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Suspended × OTHER × talazoparib × Clear all

NCT05425862 2023-12-11

REPAIR

Peter MacCallum Cancer Centre, Australia

Phase 1 Suspended

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon ⚡